Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay Save
Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.